Efficacy of Brincidofovir as prophylaxis against HSV and VZV in hematopoietic cell transplant recipients

BACKGROUND: Allogeneic hematopoietic cell transplant (HCT) recipients are at risk for herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections. Routine prophylaxis with acyclovir is recommended during periods of immunosuppression. Brincidofovir (BCV, CMX001), a lipid conjugate of cidof...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Transpl Infect Dis
Glavni autori: Lee, Yeon Joo, Neofytos, Dionysios, Kim, Seong Jin, Cheteyan, Leslie, Huang, Yao-Ting, Papadopoulos, Esperanza B., Jakubowski, Ann A., Papanicolaou, Genovefa A
Format: Artigo
Jezik:Inglês
Izdano: 2018
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6310478/
https://ncbi.nlm.nih.gov/pubmed/30120866
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/tid.12977
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items